ArticleCancer medicine2018
Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China.
Article in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- MicroRNA regulation of macrophage polarization in lung cancer: Regulatory networks and therapeutic potential (Review).International journal of oncology · 2026Review
- MiRNA expression analysis from circulating exosomes in Barrett's esophagus patients with visceral obesity.Scientific reports · 2025Article
- Exosomal miR-106a-5p derived from intermittently hypoxic non-small-cell lung cancer increases tumor malignancy.Physiological reports · 2024Article
- Matrix metalloproteinase‑1 and microRNA‑486‑5p in urinary exosomes can be used to detect early lung cancer: A preliminary report.Oncology letters · 2024Article
- Role of miR‑181a‑5p in cancer (Review).International journal of oncology · 2023Review
- lncRNA ASBEL and lncRNA Erbb4-IR reduce chemoresistance against gemcitabine and cisplatin in stage IV lung squamous cell carcinoma via the microRNA-21/LZTFL1 axis.American journal of cancer research · 2023Article
- Article
- Comparative Analysis of Free-Circulating and Vesicle-Associated Plasma microRNAs of Healthy Controls and Early-Stage Lung Cancer Patients.Pharmaceutics · 2022Article
- Article
- MicroRNA-106a-5p promotes the proliferation, autophagy and migration of lung adenocarcinoma cells by targeting LKB1/AMPK.Experimental and therapeutic medicine · 2021Article
- Exosome-Derived microRNA: Efficacy in Cancer.Cureus · 2021Review
- Early Diagnosis of Oral Squamous Cell Carcinoma (OSCC) by miR-138 and miR-424-5p Expression as a Cancer Marker.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs.Diagnostics (Basel, Switzerland) · 2021Article
- Article
- Downregulation of long non-coding RNA B-Raf proto-oncogene-activated non-coding RNA reverses cisplatin resistance in laryngeal squamous cell carcinoma.Archives of medical science : AMS · 2021Article
- Diagnostic value of oncofetal miRNAs in cancers: A comprehensive analysis of circulating miRNAs in pan-cancers and UCB.Cancer biomarkers : section A of Disease markers · 2021Article
- Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy.Frontiers in molecular biosciences · 2021Review
- MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.Thoracic cancer · 2020Article
- Exosomal miRNAs as biomarkers for diagnostic and prognostic in lung cancer.Cancer medicine · 2020Review
- Elevated expression of exosomal microRNA-21 as a potential biomarker for the early diagnosis of pancreatic cancer using a tethered cationic lipoplex nanoparticle biochip.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulated microRNAs (miRNAs) in the plasma of patients with lung squamous cell carcinoma (LSCC) might serve as biomarkers for LSCC diagnosis. The expression of miRNAs was performed using quantitative reverse transcription-polymerase chain reaction (qRT-PCR) on the basis of Exiqon panels in the initial screening phase including three male LSCC pool samples and one normal control (NC) pool sample (per 10 samples were pooled as one pool sample). After the training (32 LSCC vs. 31 NCs), the testing (55 LSCC vs. 55 NCs), and the external validation (15 LSCC vs. 15 NCs) stages via qRT-PCR, a four-miRNA signature (miR-181a-5p, miR-21-5p, miR-106a-5p, and miR-93-5p) was identified for LSCC detection. Areas under the receiver operating characteristic (ROC) curve (AUC) of the four-miRNA panel for the training, the testing, and the external validation phases were 0.795, 0.827, and 0.914, respectively. Then, the four miRNAs were explored in LSCC tissue samples (23 LSCC vs. 23 NCs), and their expression was significantly up-regulated. However, none of the four miRNAs found significantly up-regulated in plasma exosomes expect miR-93-5p with borderline significance (16 LSCC vs. 16 NCs). In summary, our study established a four-miRNA peripheral plasma signature, which contributed to diagnosing male LSCC patients in China to a certain degree.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.